GlassScriptPhysician profile
Moustafa Banna
NPI 1003009861
$24,684.88
in general payments reported to CMS, 2019-2025
41 companies · $3,126 in 2025
The $3,126 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,548 · 2020: $4,672 · 2021: $1,918 · 2022: $2,987 · 2023: $2,639 · 2024: $2,795 · 2025: $3,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,559.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $10,105.91 | 2019-2025 | General - Therapies, Watchman Flx, General - Tachy |
| Actelion Pharmaceuticals US, INC. | $1,737.04 | 2021-2025 | Uptravi, Opsumit |
| Amgen INC. | $1,350.72 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,292.22 | 2019-2025 | |
| Cardiva Medical, INC. | $1,015.11 | 2021-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $986.82 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $841.34 | 2021-2025 | Camzyos, Eliquis |
| Abiomed | $830.28 | 2019-2025 | Impella |
| Edwards Lifesciences Corporation | $827.86 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Heartflow, INC. | $676.20 | 2023-2025 | Ffrct |
| Astrazeneca Pharmaceuticals LP | $546.72 | 2019-2025 | Farxiga |
| Abbott Laboratories | $520.05 | 2019-2025 | Aveir, Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $509.35 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $436.42 | 2021-2025 | Winrevair, Verquvo |
| Medtronic Vascular, INC. | $370.16 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moustafa Banna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.